VIV:TSX.V; VIVXF:OTCQB

Avivagen Inc.

Avivagen is developing and commercializing products that promote health in animals and humans. The Corporation’s unique OxC-beta™ technology is a proprietary, first-in-class source of β-carotene-oxygen copolymer compounds that confer a variety of non-vitamin A health benefits. These benefits have wide, global utility, including replacement of antibiotics in livestock feeds, as well as for food-production conditions where antibiotics cannot be used, and supporting good health in companion animals.
VIV:TSX.V VIVXF:OTCQB

Expert Comments:

The positive results of two studies of Avivagen's OxC-beta in broiler poultry are slated for publication in Poultry Science.
read more >

David Bautz, Zacks Small-Cap Research

(3/8/21)
"Avivagen Inc. delivered a total of approximately 5 t of OxC-beta Livestock last year, thus the orders received thus far for 2021 already exceed last year's totals. . .the company has announced that two publications describing trials performed with OxC-beta will be published in leading, peer-reviewed scientific journals." —Zacks Small-Cap Research

Joseph Gomes, Noble Capital Markets

(3/5/21)
"Another manuscript reporting the benefits of Avivagen Inc.'s OxC-beta Livestock, this time for broiler poultry, has been approved for publication by Poultry Science, a leading peer-reviewed journal; in the two trials reported on, OxC-beta groups achieved significantly improved growth performance measures over the control groups. These peer-reviewed publications not only validate existing customers but provide confidence to new customers to adopt OxC-beta."

Joseph Gomes, Noble Capital Markets

(3/1/21)
"We are initiating research coverage on Avivagen Inc. with an Outperform rating. . .we believe the company is at an inflection point with significant sales increases just around the corner and presents a favorable risk/reward proposition."

Avivagen Inc. reported that data from a New Zealand OxC-betaT™ Livestock Dairy Trial for use against sub-clinical mastitis has been published in a top-tier international veterinary science journal.
read more >
Avivagen Inc. reported it has secured a six tonne order for OxC-beta™ Livestock from a new customer in Queretaro City, Mexico.
read more >

David Bautz, Zacks Small-Cap Research

(12/23/20)
"Avivagen Inc. achieved a number of important milestones in 2020, including approval of OxC-beta in Brazil and Malaysia, a record 4 ton order from UNAHCO, the company's distribution partner in the Philippines, and a 10 ton order from Industrias Melder in Mexico. FY20 revenues were CA$1.2M, and for FY21 we are currently forecasting sales of CA$3M based on increased order sizes from current customers and expansion of the customer base." —Zacks Small-Cap Research

Avivagen Inc. reported FY/20 audited financial results that included a 20.5% increase in YoY revenue.
read more >

David Bautz, Zacks Small-Cap Research

(9/8/20)
"Avivagen Inc. announced financial results for Q3 FY20 that ended July 31, 2020; the company reported revenues of CA$612,530, an increase of CA$600,046 compared to Q3 FY19, which was driven by two major sales of OxC-beta during the quarter and the largest ever orders from Mexico-based Industrias Melder and Philippines-based UNAHCO. In addition, during the quarter, regulatory approval was secured in Brazil." —Zacks Small-Cap Research

SmallCapsDaily

(7/23/20)
"Enhancing livestock health without the use of antibiotics has become a must in order to prevent the emergence of deadly diseases including so called superbugs. Avivagen Inc. is a Life Sciences player that caters directly to this need and is at a very interesting juncture today. The company is building a compelling growth story as it has gone on to receive numerous country approvals across many large livestock markets in the world."

More Expert Comments

Experts Following This Company

Joseph Gomes – Wm Smith & Co.

Company News

1/27/2021 – IIROC Trading Resumption - VIV

The information provided above is from analysts, newsletters, the company and other contributors.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Effective natural substitute for antibiotics in animal feed
 
Six families of patents extending beyond 2035
 
Antibiotic ban in animal feed being led by Governments
catalyst Calendar
Q1
2019
Nutraceutical deal/JV
Q3
2019
GRAS approval for livestock in the USA
Q4
2019
Chinese approval for livestock